CYTOKINETICS, INC. |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-24 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
| 06-17 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
Chart calendar Cytokinetics, Inc.
e47970f0f54b6665107307f78.eLvsogFq9Av3_xOdRxO0PPs2fKrEFeOA8ZA4zPkdxnk.LP6pzDIywSalnEnINXj8CZwPDeyxYKr3vPNqo40rqysvzp7VXhmbbsWdWg~a60b8e2e7061cc8ece6f7f6db774eae2
Upcoming events on Cytokinetics, Inc.
Past events on Cytokinetics, Inc.
| 10/06/2024 16:20 | Goldman Sachs Global Healthcare Conference |
| 05/06/2024 15:00 | Jefferies Global Healthcare Conference |
| 15/05/2024 18:00 | Annual General Meeting |
| 13/05/2024 16:00 | European Society of Cardiology Heart Failure Congress |
| 13/05/2024 14:33 | European Society of Cardiology Heart Failure Congress - Caroline Coat |
| 13/05/2024 14:21 | European Society of Cardiology Heart Failure Congress - Gregory Lewis, M.D |
| 13/05/2024 14:09 | European Society of Cardiology Heart Failure Congress - Martin Maron, M.D |
| 08/05/2024 21:30 | Q1 2024 Earnings Call |
| 08/05/2024 21:00 | Q1 2024 Earnings Release |
| 08/04/2024 19:15 | Needham Healthcare Conference |
| 07/04/2024 19:00 | American College of Cardiology Scientific Meeting - Sara Saberi |
| 07/04/2024 18:00 | American College of Cardiology Scientific Meeting - Nosheen Reza |
| 07/04/2024 14:15 | American College of Cardiology Scientific Meeting - Tristan B. Post |
| 06/04/2024 15:45 | American College of Cardiology Scientific Meeting - Morris M. Kim |
| 13/03/2024 13:00 | Barclays Global Healthcare Conference |
| 11/03/2024 | Jefferies Biotech on the Bay Summit |
| 11/03/2024 17:20 | Leerink Partners Global Biopharma Conference |
| 27/02/2024 21:30 | Q4 2023 Earnings Call |
| 27/02/2024 21:00 | Q4 2023 Earnings Release |
| 13/02/2024 15:40 | Oppenheimer Healthcare Life Sciences Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 26,9 29,4 -8.54% | 55,8 58,3 -4.18% | 70,4 20,7 240.58% | 94,6 99,3 -4.74% | 7,53 24,2 -68.83% | 32,1 |
|
EBITDA Million USD | Released Forecast Spread | -97,6 -89,0 -9.62% | -92,1 -75,9 -21.38% | -184 -229 19.61% | -318 -298 -6.85% | -484 -396 -22.3% | -450 |
|
EBIT Million USD | Released Forecast Spread | -98,9 -97,9 -0.95% | -93,9 -83,0 -13.16% | -186 -226 17.38% | -324 -301 -7.58% | -496 -441 -12.62% | -466 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -122 -121 -0.86% | -127 -113 -12.24% | -215 -246 12.62% | -389 -361 -7.62% | -526 -469 -12.11% | -488 |
|
Net income Million USD | Released Forecast Spread | -122 -119 -2.23% | -127 -113 -12.57% | -215 -249 13.69% | -389 -366 -6.17% | -526 -475 -10.9% | -490 |
|
EPS USD | Released Forecast Spread | -2,11 -2,07 -2.13% | -1,97 -1,77 -11.61% | -2,80 -3,27 14.24% | -4,33 -4,05 -6.85% | -5,45 -4,88 -11.61% | -4,44 |
| Announcement Date | 03/03/20 | 25/02/21 | 24/02/22 | 01/03/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2020 S1 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 7,42 8,43 -11.98% | 1,15 4,72 -75.66% | 89,0 3,73 2284.05% | 2,52 3,23 -22.24% | 1,96 7,10 -72.44% | 4,61 2,50 84.75% | 0,87 6,05 -85.68% | 0,38 21,6 -98.25% | 1,67 13,3 -87.39% | 0,84 0,91 -7.9% | 21,0 | 2,16 | 4,28 | 1,17 | 2,33 |
|
EBITDA Million USD | Released Forecast Spread | -76,5 -82,0 6.69% | -9,47 -85,0 88.86% | -107 -97,0 -10.34% | -125 -112 -11.94% | -123 -110 -11.48% | -120 -77,3 -55.59% | -120 -92,0 -30.88% | -121 -33,4 -262.55% | -103 | -113 | -103 | ||||
|
EBIT Million USD | Released Forecast Spread | -62,7 -58,6 -7.03% | -77,9 -75,3 -3.33% | -10,9 -84,1 87.07% | -108 -97,9 -10.79% | -127 -105 -20.43% | -124 -109 -14.67% | -122 -105 -16.23% | -122 -69,7 -75.47% | -127 -89,9 -41.77% | -126 -117 -7.98% | -112 | -114 | -111 | -120 | -118 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -80,2 -75,4 -6.35% | -89,4 -79,2 -13% | -19,8 -87,9 77.45% | -142 -103 -37.55% | -137 -113 -21.26% | -131 -117 -12.57% | -129 -112 -15.21% | -129 -80,2 -61.29% | -137 -95,9 -42.7% | -136 -122 -10.94% | -112 | -119 | -123 | -114 | -118 |
|
Net income Million USD | Released Forecast Spread | -80,2 -75,4 -6.35% | -89,4 -79,1 -13.01% | -19,8 -89,5 77.87% | -142 -105 -35.87% | -137 -114 -20.26% | -131 -116 -12.79% | -129 -113 -14.34% | -129 -76,9 -68.35% | -137 -95,8 -42.89% | -136 -119 -13.71% | -112 | -119 | -121 | -111 | -115 |
|
EPS USD | Released Forecast Spread | -1,05 -0,95 -10.01% | -0,23 -1,04 77.84% | -1,52 -1,17 -29.94% | -1,45 -1,21 -19.36% | -1,38 -1,21 -13.85% | -1,34 -1,16 -16% | -1,35 -0,74 -83.4% | -1,38 -0,99 -39.72% | -1,33 -1,15 -15.72% | -0,94 | -1,10 | -1,05 | -1,14 | -1,06 | |
| Announcement Date | 06/08/20 | 04/05/22 | 04/08/22 | 03/11/22 | 01/03/23 | 04/05/23 | 03/08/23 | 02/11/23 | 27/02/24 | 08/05/24 | - | - | - | - | - |
More events
Past sector events for Cytokinetics, Inc.
| 05/06/2024 08:51 | PHARMAESSENTIA CORPORATION: May 2024 Sales and Revenue Release |
| 17/05/2024 12:00 | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 16/05/2024 12:46 | BIOCON LIMITED: Q4 2024 Earnings Release |
| 16/05/2024 06:00 | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 15/05/2024 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
| 15/05/2024 13:05 | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
| 15/05/2024 12:00 | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
| 14/05/2024 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
| 14/05/2024 21:05 | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 14/05/2024 21:00 | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
- Stock Market
- Equities
- CYTK Stock
- Stock
- Calendar Cytokinetics, Inc.
